Table 3. . Immunotherapy in esophageal, gastric and gastroesophageal junction cancer.

Trial	Subtype adeno/SCC PD-L1+/any	Phase	n	Line of therapy	Intervention	Outcome RR† (%)	Ref.
KEYNOTE-012 Muro et al.	Adeno	Ib	39	>1	Pembrolizumab	22	[99]
CheckMate 032 Janjigian et al.	Both	I/II	160	≥2	Nivo(3) (n = 59) Nivo(1) + ipi(3) (n = 49) Nivo(3) + ipi(1) (n = 52)	12 24 8	[27]
Kudo et al.	SCC	II	65	>2	Nivolumab	17	[100]
KEYNOTE-059 Fuchs et al.	Adeno	II	259 25	≥3 1	Pembrolizumab 3L Pembrolizumab + 5-FU + cisplatin 1l	11.2 60	[24,25]
ATTRACTION-2 Kang TS et al.	Adeno	III	493	≥3	Nivolumab vs placebo	5.3 vs 4.1 m HR: 0.63 (p < 0.0001)	[101]
CheckMate 649 Moehler et al.	Adeno	III	1266	1	Nivo/ipi vs nivo vs chemotherapy (oxaliplatin + fluoropyrimidine)	Ongoing	[102]
CheckMate 649 Janjigian et al.	Both	III	870	1	Nivo/ipi vs chemotherapy (oxaliplatin + fluoropyrimidine)	Ongoing	[103]
KEYNOTE-061 Ohtu et al.	Adeno (HER2+)	III	720	2	Pembrolizumab vs paclitaxel	Ongoing	[104]
KEYNOTE-062 Tabernero et al.	Adeno carcinoma (PD-L1+/HER2 -)	III	750	1	Pembrolizumab vs pembro + cisplatin + 5FU vs placebo + cisplatin + 5-FU	Ongoing	[105]

^†RR except for ATTRACTION-2 (overall survival).

RR: Response rate; SCC: Squamous cell carcinoma.